BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. 2015

Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
Department of Chemistry, Guangxi University, Nanning 530004, PR China.

A series of phenylpropanoid derivatives were synthesized, and their anti-hepatitis B virus (HBV) activity was evaluated in HepG 2.2.15 cells. Most of the synthesized derivatives showed effective anti-HBV activity. Of these compounds, compound 4c-1 showed the most potent anti-HBV activity, demonstrating potent inhibitory effect not only on the secretion of HBsAg (IC50 = 14.18 μM, SI = 17.85) and HBeAg (IC50 = 6.20 μM, SI = 40.82) secretion but also HBV DNA replication (IC50 = 23.43 μM, SI = 10.80). The structure-activity relationships (SARs) of phenylpropanoid derivatives had been discussed, which were useful for phenylpropanoid derivatives to be explored and developed as novel anti-HBV agents. Moreover, the docking study of all synthesized compounds inside the HLA-A protein (PDB ID: 3OX8) active site were carried out to explore the molecular interactions and a molecular target for activity of phenylpropanoid derivatives with the protein using a moe-docking technique. This study identified a new class of potent anti-HBV agents.

UI MeSH Term Description Entries
D010636 Phenols Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.
D004261 DNA Replication The process by which a DNA molecule is duplicated. Autonomous Replication,Replication, Autonomous,Autonomous Replications,DNA Replications,Replication, DNA,Replications, Autonomous,Replications, DNA
D006513 Hepatitis B e Antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G. HBeAg,Hepatitis B e Antigen,Hepatitis Be Antigen,e Antigen,e Antigens,HBe Ag-1,HBe Ag-2,Hepatitis Be Antigens,Antigen, Hepatitis Be,Antigen, e,Antigens, Hepatitis Be,Antigens, e,Be Antigen, Hepatitis,Be Antigens, Hepatitis
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015234 HLA-A Antigens Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts. Antigens, HLA-A,HLA-A,Antigens, HLA A,HLA A Antigens

Related Publications

Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
Potent arylamide derivatives as dual-target antifungal agents: Design, synthesis, biological evaluation, and molecular docking studies.
June 2020, Bioorganic chemistry,
Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
Design, synthesis, biological evaluation, and molecular docking of chalcone derivatives as anti-inflammatory agents.
February 2017, Bioorganic & medicinal chemistry letters,
Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
Design, synthesis, molecular docking, and biological evaluation of coumarin-thymidine analogs as potent anti-TB agents.
May 2023, Archiv der Pharmazie,
Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
Synthesis, biological evaluation and molecular docking studies of novel diosgenin derivatives as anti-inflammatory agents.
October 2022, Bioorganic chemistry,
Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents.
December 2015, Bioorganic chemistry,
Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
New nitazoxanide derivatives: design, synthesis, biological evaluation, and molecular docking studies as antibacterial and antimycobacterial agents.
December 2023, RSC medicinal chemistry,
Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
Synthesis, biological evaluation and molecular docking studies of resveratrol derivatives possessing curcumin moiety as potent antitubulin agents.
January 2012, Bioorganic & medicinal chemistry,
Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
Hybridized Quinoline Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and Molecular Docking.
January 2019, Anti-cancer agents in medicinal chemistry,
Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
Novel Benzotriazole-β-lactam Derivatives as Antimalarial Agents: Design, Synthesis, Biological Evaluation and Molecular Docking Studies.
January 2024, Chemistry & biodiversity,
Sheng Liu, and Wanxing Wei, and Yubin Li, and Xu Liu, and Xiaoji Cao, and Kechan Lei, and Min Zhou
Synthesis, Molecular Docking Studies and Biological Evaluation of Thiazolyl Hydrazone Derivatives of Chromone-3-carbaldehyde as Potent Anti-Oxidant and Anti-Inflammatory Agents.
April 2024, Medicinal chemistry (Shariqah (United Arab Emirates)),
Copied contents to your clipboard!